期刊文献+

Eudragit~NE 30D对药物释放稳定性的影响因素探讨 被引量:3

Discussion on the influencing factors of Eudragit~ NE 30D on the stability of drug release
原文传递
导出
摘要 Eudragit~ NE 30D作为一种常用的缓释包衣、缓释骨架及掩味包衣材料,在药物制剂中应用广泛。而该类水分散体成膜机理较为复杂,对药物释放控制存在不稳定性现象,即物理老化,也是目前该品种应用中存在的最为突出的问题。本文基于丙烯酸树脂成膜机理研究,结合国内外相关文献报道,对Eudragit~ NE 30D物理老化问题的解决及预防措施进行归纳总结,从而促进其在药物制剂,特别是在缓控释制剂中的应用。 Eudragit NE 30D, which is commonly used as a sustained release coating and matrix and taste masking material, has a wide application in the pharmaceutical preparations. The formation of film coatings from the aqueous polymer dispersions is a complex process, highly dependent on additives and process parameters. Release instability of modified release coatings from aqueous polymer dispersions, which is known as physical aging, is a frequently described problem that hinders the general application of such dispersions. Based on the film formation mechanism from aqueous dispersions and the relevant literature reports, the present paper reviewed the technical methods to solve or prevent the physical aging of Eudragit~ NE 30D, which would facilitate the application of the material in pharmaceutical preparations, especially the sustained controlled preparations and taste masking.
出处 《中国新药杂志》 CAS CSCD 北大核心 2017年第10期1180-1184,共5页 Chinese Journal of New Drugs
关键词 Eudragit NE 30D 物理老化 药物释放 稳定性 Eudragit NE 30D physical aging drug release stability
  • 相关文献

参考文献2

二级参考文献21

  • 1施文,王永铭,李端,李少丽,颜敏,陈斌艳,程能能.4种非甾体抗炎药治疗类风湿关节炎的成本-效果分析[J].中国新药与临床杂志,2004,23(8):513-517. 被引量:10
  • 2姜贵云,姚立新,鞠智卿.非类固醇抗炎药在类风湿关节炎康复治疗中的应用[J].中国临床康复,2006,10(16):121-123. 被引量:1
  • 3BENGT L, RAGNARSSON G, HJARTSTAM J. Osmotic pumping as a release mechanism for membrane-coated drug formulations [J]. Int J Pharm,1989,56(3) :261-272.
  • 4RAINSFORD KD. Profile and mechanisms of gastrointestinal and other side effects of nonsteroidal anti-inflammatory drugs (NSAIDs) [J]. Am J Med,1999,107(6A) :S27S - S35S.
  • 5马祥志,李敏谊.合成方法对羧甲基淀粉吸水溶胀性能的影响[J].广东药学院学报,1997,13(1):7-10. 被引量:7
  • 6Algieri C, Drioli E, Donato L. Development of mixed matrix membranes for controlled release of ibuprofen[J]. J Appl Polym Sci, 2013,128(1) : 754.
  • 7Sharma P, Guttikar S, Solanki G, et al. Determination of (S) - ( + ) -and (R) - ( - ) -ibuprofen enantiomers in human plasma after chiral precolumn derivatization by reversed- phase LC-ESI-MS/MS [J]. Bioanalysis, 2012,4 (24) : 2 909.
  • 8Wang JJ, Dai DY, Qiu QQ, et al. Evaluation of anti-in- flammatory and analgesic effects of synthesized deriva- tives of ibuprofen[J]. Chem Biol Drug Des, 2015,85 (5) : 623.
  • 9Yi HG, Chi MH, Kim YI, et al. Formulation of a exten- ded release tablet containing dexibuprofen[J]. Arch Pharm Res,2008,31(12):l 637.
  • 10Kim SR, Kim JK, Park JS, et al. Dry elixir formulations of dexibuprofen for controlled release and enhanced oral bioavailability[J]. Int J Pharma, 2011,404 (1/2) : 301.

共引文献11

同被引文献39

引证文献3

二级引证文献3

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部